BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Misses Revenue Estimates

BioXcel Therapeutics, Inc. (BTAI) came out with a quarterly loss of $2.18 per share versus the Zacks Consensus Estimate of a loss of $1.54. This compares to a loss of $5.12 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -41.56%. A quarter ago, it was expected that this company would post a loss of $2.3 per share when it actually produced a loss of $2.45, delivering a surprise of -6.52%.Over the last four quarters, the company ...